Identification of a novel inhibitor of breast cell growth that is down-regulated by estrogens and decreased in breast tumors.

Lifetime exposure to estrogens is a major risk factor in breast cancer, but the mechanism for this action is not fully defined. To better determine this mechanism, the activation domain of estrogen receptor (ER) alpha was used in yeast two-hybrid screenings. These screenings resulted in the identification of a novel antiproliferative protein, estrogen down-regulated gene 1 (EDG1), of which the mRNA and protein were shown to be down-regulated directly by estrogens. Our studies additionally suggested an important role for EDG1 in ER alpha-mediated breast cancer development. Analysis of 43 invasive breast cancer samples and 40 adjacent normal breast samples demonstrated EDG1 protein levels to be significantly higher in normal breast epithelial tissue as compared with breast epithelial tumor tissue. EDG1 expression levels were also correlated with the proliferation activity and ER alpha status of the tumors to examine the prognostic value of EDG1 in invasive breast tumors. EDG1 expression was more disassociated from proliferative activity as compared with ER alpha expression in tumor cells. A growth regulatory function for EDG1 is additionally indicated by studies wherein overexpression of EDG1 protein in breast cells resulted in decreased cell proliferation and decreased anchorage-independent growth. Conversely, inhibiting EDG1 expression in breast cells resulted in increased breast cell growth. Thus, we have identified a novel growth inhibitor that is down-regulated by estrogens and colocalizes with ER alpha in breast tissue. These studies support a role for EDG1 in breast cancer.

[1]  Kornelia Polyak,et al.  Cellular and molecular targets of estrogen in normal human breast tissue. , 2002, Cancer research.

[2]  M. Montano,et al.  Regulation of prothymosin α by estrogen receptor α: molecular mechanisms and relevance in estrogen-mediated breast cell growth , 2002, Oncogene.

[3]  M. Siddiqui,et al.  Structure, expression, and functional characterization of the mouse CLP-1 gene. , 2002, Gene.

[4]  Suzanne M Johnson,et al.  Sporadic breast cancer in young women: Prevalence of loss of heterozygosity at p53, BRCA1 and BRCA2 , 2002, International journal of cancer.

[5]  K. Polyak,et al.  Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression) , 2002, Oncogene.

[6]  S. Safe,et al.  Estrogen Regulation of Cyclin D1 Gene Expression in ZR-75 Breast Cancer Cells Involves Multiple Enhancer Elements* , 2001, The Journal of Biological Chemistry.

[7]  J. Craft,et al.  Clonal origins of human breast cancer , 2001, The Journal of pathology.

[8]  Á. Pascual,et al.  Nuclear hormone receptors and gene expression. , 2001, Physiological reviews.

[9]  I. Ellis,et al.  Loss of Heterozygosity in Bilateral Breast Cancer , 2000, Breast Cancer Research and Treatment.

[10]  J. Gustafsson,et al.  The Hairy and Enhancer of Split homologue-1 (HES-1) mediates the proliferative effect of 17β-estradiol on breast cancer cell lines , 2000, Oncogene.

[11]  R. Hubbard,et al.  A structural biologist's view of the oestrogen receptor , 2000, The Journal of Steroid Biochemistry and Molecular Biology.

[12]  G. Hager,et al.  Trafficking of nuclear receptors in living cells , 2000, The Journal of Steroid Biochemistry and Molecular Biology.

[13]  M J Bissell,et al.  Tissue architecture and breast cancer: the role of extracellular matrix and steroid hormones. , 2000, Endocrine-related cancer.

[14]  S. Kyo,et al.  Estrogen activates telomerase. , 1999, Cancer research.

[15]  K. Yamaguchi,et al.  Cloning of Hexamethylene-bis-acetamide-inducible Transcript, HEXIM1, in Human Vascular Smooth Muscle Cells , 1999 .

[16]  E. Alarid,et al.  Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. , 1999, Molecular endocrinology.

[17]  B. Katzenellenbogen,et al.  An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Anil K. Jaiswal,et al.  Transcriptional Regulation of the Human Quinone Reductase Gene by Antiestrogen-liganded Estrogen Receptor-α and Estrogen Receptor-β* , 1998, The Journal of Biological Chemistry.

[19]  A. Børresen-Dale,et al.  Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters. , 1998, Cancer research.

[20]  G. Casey,et al.  Four regions of allelic imbalance on 17q12‐qter associated with high‐grade breast tumors , 1997, Genes, chromosomes & cancer.

[21]  A. Howell,et al.  Dissociation between steroid receptor expression and cell proliferation in the human breast. , 1997, Cancer research.

[22]  K. Patil,et al.  Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Maggi,et al.  Oligonucleotide squelching reveals the mechanism of estrogen receptor autologous down-regulation. , 1997, Molecular endocrinology.

[24]  B. Katzenellenbogen,et al.  The quinone reductase gene: a unique estrogen receptor-regulated gene that is activated by antiestrogens. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Niederacher,et al.  Patterns of allelic loss on chromosome 17 in sporadic breast carcinomas detected by fluorescent‐labeled microsatellite analysis , 1997, Genes, chromosomes & cancer.

[26]  B. Katzenellenbogen.  Estrogen receptors: bioactivities and interactions with cell signaling pathways. , 1996, Biology of reproduction.

[27]  X. Breakefield,et al.  Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells , 1996, Journal of virology.

[28]  B. Katzenellenbogen,et al.  Hormone binding and transcription activation by estrogen receptors: Analyses using mammalian and yeast systems , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[29]  N. Gas,et al.  Effects of differentiation‐inducing agents on maturation of human MCF‐7 breast cancer cells , 1990, Journal of cellular physiology.

[30]  M. Lippman,et al.  Role of an estrogen receptor-dependent mechanism in the regulation of estrogen receptor mRNA in MCF-7 cells. , 1989, Molecular endocrinology.

[31]  P. Chambon,et al.  Regulation of the estrogen receptor in MCF-7 cells by estradiol. , 1988, Molecular endocrinology.

[32]  R. Dickson,et al.  Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. , 1987, Endocrine reviews.

[33]  McGuire Wl,et al.  Hormone receptors: their role in predicting prognosis and response to endocrine therapy. , 1978, Seminars in oncology.

[34]  S. Chevillard,et al.  Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer , 2005, Breast Cancer Research and Treatment.

[35]  J. Russo,et al.  Role of Hormones in Mammary Cancer Initiation and Progression , 2004, Journal of Mammary Gland Biology and Neoplasia.

[36]  S. Nass,et al.  The Loss of Estrogen and Progesterone Receptor Gene Expression in Human Breast Cancer , 2004, Journal of Mammary Gland Biology and Neoplasia.

[37]  R. Lothe,et al.  Evaluation of breast cancer polyclonality by combined chromosome banding and comparative genomic hybridization analysis. , 2001, Neoplasia.

[38]  G. Sourvinos,et al.  Microsatellite instability and loss of heterozygosity in primary breast tumours. , 1997, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.